Comparison of the Benefit of Chromoendoscopy in Addition to High Definition White Light and Narrow Band Imaging for the Prediction of Submucosal Invasive Cancer in Colonic Lesions (LANS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03506321 |
|
Recruitment Status :
Recruiting
First Posted : April 24, 2018
Last Update Posted : March 23, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colonic Adenoma Colon Polyp Submucosal Invasive Colon Adenocarcinoma Colorectal Cancer | Diagnostic Test: chromoendoscopy, high definition white light and narrow band imaging | Not Applicable |
Wide-field (WF) EMR is now accepted as a safe and effective alternative to surgery for removal of large (>20mm) laterally spreading lesions (LSLs).
Assessment of the risk of submucosal invasive cancer (SMIC) is paramount to determining whether a lesion should be attempted for resection by endoscopic mucosal resection (EMR). Lesions that are at high risk for invading the submucosa should either be referred for surgery or in selected cases may be removed by endoscopic submucosal dissection (ESD) in an en bloc fashion to assess SMIC accurately. Tools to assess the likelihood of SMIC endoscopically include analysis of the Kudo pit-pattern (KPP) combined with assessment of morphology as per Paris classification.
KPP analysis is useful to predict histology based on the microarchitecture of pits, epithelial crests or ridges. It thus provides an assessment of risk of sub-mucosal invasion of superficial lesions. There are five categories; with Type 1 and 2 being non-tumours i.e. benign lesion, as compared to Type 3-5 which are tumours ranging from pre-cancerous adenomas (tubular or villous adenoma) to invasive cancer.
Assessment of lesion morphology at WF-EMR using the Paris Classification and analysis of the surface pit-pattern are an integral part of identifying lesions suitable for EMR.
As per the Paris Classification superficial lesions in the colon are divided into; polypoid, non-polypoid and mixed types. Non-polypoid lesions are further divided into slightly raised (0-IIa), flat (0-IIb), depressed surface (0-IIc) or mixed types such as a flat lesion with a nodule (0-IIa+b). The later generally have a greater risk for sub-mucosal invasion (SMI) than polypoid lesions and can be as high as 35-40%. Flat lesions are referred to as laterally spreading lesions (LSLs) if greater than 10mm. There are two distinct subtypes; non-granular vs granular. Granular LSLs exhibit a lower risk of SMI as compared to non-granular LSLs.
Expert opinion suggests that differentiating the KPP in large LSLs (>20mm) requires chromoendoscopy or magnifying endoscopy. This can be a time intensive process. New advances in optics focusing on manipulating the wavelength of the light source; e.g. narrow band imaging (NBI) with the Olympus platform or Fujinon intelligent colour enhancement (FICE) with Fuji have become readily available, and show potential, particularly when combined with magnification, in discriminating the KPP and therefore predicting risk for SMIC. These technologies essentially provide virtual chromoendoscopy. Their diagnostic accuracy has been shown to be comparable to indigo-carmine chromoendoscopy. Both chromoendoscopy and NBI have shown superiority in accurately differentiating between neoplastic and non-neoplastic lesions as compared to high definition white light (HD-WL) endoscopy. In addition NBI has been shown to have a negative predictive value of 98% in assessing residual or recurrent adenoma (RRA) at an EMR scar.
No studies to date have assessed the use of chromoendoscopy and the subsequent benefit of high-definition imaging (HD-WL + NBI) in predicting SMIC and RRA at an EMR scar.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 150 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Diagnostic |
| Official Title: | Comparative Analysis of the Incremental Benefit of Chromoendoscopy in Addition to High Definition White Light (HD-WL)and Narrow Band Imaging (NBI) for the Prediction of Submucosal Invasive Cancer Within Laterally Spreading Lesions (LSLs) and in Determining the Presence of Residual or Recurrent Adenoma at a Post Endoscopic Resection Scar |
| Actual Study Start Date : | February 7, 2018 |
| Estimated Primary Completion Date : | February 7, 2022 |
| Estimated Study Completion Date : | February 7, 2022 |
| Arm | Intervention/treatment |
|---|---|
|
LANS
Lesions are assessed with chromoendoscopy, HD-WL & NBI
|
Diagnostic Test: chromoendoscopy, high definition white light and narrow band imaging
Chromoendoscopy, high definition white light and narrow band imaging are compared for predicting submucosal invasion within laterally spreading lesions in the colon and determining the presence of residual or recurrent adenoma at the post endoscopic resection scar |
- Compare chromoendoscopy predictions and HD-WL/NBI predictions of submucosal invasive cancer (SMIC) and residual or recurrent adenoma (RRA) to compare correlation with histological findings [ Time Frame: Three years ]
- Accurate histologic correlation as predicted by Kudo pit pattern classification [ Time Frame: Three years ]
- Compare inter-observer agreement of presence of SMIC using high definition imaging and chromoendoscopy [ Time Frame: Three years ]
- Compare the difference between live endoscopic assessment and use of carefully selected endoscopic images to predict SMIC [ Time Frame: Three years ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients able to give informed consent to involvement in trial. For patients who do not speak English, an interpreter will be asked to translate the informed consent
- Patients referred to Westmead and Auburn Hospital Endoscopy Unit for a colonoscopy for all indications
Exclusion Criteria:
- Patient's with known colonic strictures/stenosis
- Patient's with active inflammatory bowel disease
- Pregnancy
- Patients who did not consent to study
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03506321
| Contact: Michael J Bourke, MBBS | 88905555 | michael@citywestgastro.com.au | |
| Contact: Kathleen T Goodrick, BN | 88905555 | kathleen.goodrick@health.nsw.gov.au |
| Australia, New South Wales | |
| Westmead Endoscopy Unit | Recruiting |
| Westmead, New South Wales, Australia, 2145 | |
| Contact: Kathleen Goodrick, BN 88905555 kathleen.goodrick@health.nsw.gov.au | |
| Responsible Party: | Professor Michael Bourke, Director of Gastrointestinal Endoscopy, Western Sydney Local Health District |
| ClinicalTrials.gov Identifier: | NCT03506321 |
| Other Study ID Numbers: |
HREC/16/WMEAD/392(4863) |
| First Posted: | April 24, 2018 Key Record Dates |
| Last Update Posted: | March 23, 2021 |
| Last Verified: | March 2021 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
colonoscopy Residual adenoma Recurrent adenoma |
|
Adenoma Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |